Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

FDA Approvals, Study Results, Multi-Year Collaborations, Data Presentations, and Supply Agreements - Research Report on Celgene,



 FDA Approvals, Study Results, Multi-Year Collaborations, Data Presentations,
   and Supply Agreements - Research Report on Celgene, Amgen, Biogen Idec,
                             Vertex, and Illumina

PR Newswire

NEW YORK, September 12, 2013

NEW YORK, September 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), Amgen, Inc. (NASDAQ: AMGN), Biogen Idec Inc.
(NASDAQ: BIIB), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and
Illumina, Inc. (NASDAQ: ILMN). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Celgene Corporation Research Report

On September 6, 2013, Celgene Corporation (Celgene) announced that the U.S.
Food and Drug Administration (FDA) has approved the Company's supplemental New
Drug Application (sNDA) of ABRAXANE for treating patients with metastatic
adenocarcinoma of the pancreas, in combination with gemcitabine. Jean-Pierre
Bizzari, M.D., Executive Vice President of Hematology and Oncology at Celgene
said, "For more than 15 years, treatment with gemcitabine has been the
standard of care in this disease. The addition of ABRAXANE to gemcitabine
demonstrated meaningful improvements across key efficacy outcomes, including
overall survival, with a well-characterized safety profile." Celgene further
stated that ABRAXANE in combination with gemcitabine is the first new
treatment approved for metastatic adenocarcinoma of the pancreas in nearly
eight years. The Full Research Report on Celgene Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-09-09/CELG]

--

Amgen, Inc. Research Report

On September 1, 2013, Amgen, Inc. (Amgen) announced that treatment with AMG
145 resulted in marked reduction of upto 59% in low-density lipoprotein
cholesterol (LDL-C) in an efficacy analysis of pooled data from four 12-week
Phase 2 studies that evaluated AMG 145 in patient populations with high
cholesterol. According to Amgen, AMG 145 is an investigational human
monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's
ability to remove LDL-C from the blood. Amgen further informed that it
presented the data at the ESC Congress 2013, organized by the European Society
of Cardiology, in Amsterdam. Sean E. Harper, M.D., Vice President of Research
and Development at Amgen said, "The data that we have accumulated in our Phase
2 clinical program is evidence that AMG 145 has the potential to help patients
reach their cholesterol goals. We are conducting a large and comprehensive
Phase 3 clinical program evaluating AMG 145 in multiple patient populations
and utilizing two dosing schedules, with the hopes of advancing care and
improving the lives of patients with uncontrolled high LDL cholesterol." The
Full Research Report on Amgen, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-09-09/AMGN]

--

Biogen Idec Inc. Research Report

On September 9, 2013, Biogen Idec Inc. (Biogen Idec) announced a partnership
with Isis Pharmaceuticals, Inc. (Isis) for a broad, multi-year collaboration
to leverage antisense technology to advance the treatment of neurological
diseases. Biogen Idec stated that the agreement combines its expertise in
neurology with Isis' leadership in antisense technology to develop novel
therapies to treat neurological disorders. Biogen Idec informed that in
accordance to the six-year collaboration, the Company will gain exclusive
rights to the use of Isis' antisense technology, under the terms that the
Company will make an upfront payment of $100 million for R&D and Isis will be
eligible to receive milestone payments, license fees, and royalty payments for
all treatments developed through this collaboration. The Full Research Report
on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-09/BIIB]

--

Vertex Pharmaceuticals Incorporated Research Report

On September 3, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced
that five abstracts from its cystic fibrosis (CF) research and development
program will be presented at the 27^th Annual North American Cystic Fibrosis
Conference (NACFC) to be held between October 17, 2013 and October 19, 2013,
in Salt Lake City, Utah. Vertex  informed that the Company will also present
data from a Phase 3 study of ivacaftor in non-G551D gating mutations, as well
as the data of long-term safety and efficacy for KALYDECO from the PERSIST
open-label rollover study. The Company further added that Fred Van Goor,
Ph.D., Head of Biology for Vertex's CF program, and David Rodman, M.D., Vice
President of Clinical Development for Vertex's CF program, will participate in
talks related to their work to discover and develop medicines that target the
underlying cause of CF. The Full Research Report on Vertex Pharmaceuticals
Incorporated - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-09/VRTX]

--

Illumina, Inc. Research Report

On September 4, 2013, Illumina, Inc. (Illumina) announced that it has entered
into a three-year agreement with Natera, Inc. (Natera). Illumina stated that
in accordance with the agreement, Illumina will supply Natera with the HiSeq
2500 sequencing system and associated consumable for performing the
non-invasive prenatal test (NIPT) Panorama. "We are pleased to be selected
again as Natera's next-generation sequencing system provider, to support the
growth of its Panorama™ test. Illumina's goal is to enable the rapid growth of
NIPT and the broader reproductive health market with technology, products, and
ultimately FDA-approved in vitro diagnostic systems," said Nick Naclerio,
Senior Vice President of Corporate and Venture Development at Illumina.
Matthew Rabinowitz, Ph.D., CEO of Natera added "We are pleased to continue
working with Illumina and its next-generation sequencing technology. This deal
enables a major expansion of Natera's laboratory capacity to support the
fast-growing demand for our Panorama test."  The Full Research Report on
Illumina, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-09/ILMN]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Investors' Reports

Contact: Kristi Saunders ; +1-315-982-6420 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement